Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 32
Filtrar
1.
Pak J Med Sci ; 40(4): 685-689, 2024.
Artigo em Inglês | MEDLINE | ID: mdl-38544988

RESUMO

Background & Objective: The prevalence of obesity is gradually increasing in our country and worldwide. Being obese and overweight are risk factors for chronic diseases. Obesity has a multifactorial etiology, so treatment should involve lifestyle changes, psychological strategies, pharmacologic treatment, and bariatric surgery. The present study aimed to investigate the effectiveness of the trans-theoretical stages of change (TTM SOC) model in managing adult obese and overweight patients. Methods: This prospective cohort study was conducted with 133 adults who were admitted to the Family Medicine Outpatient Clinic of Adana City Research and Training Hospital between April 1, 2017, and April 30, 2019. Socio-demographic characteristics, blood pressures, anthropometric measurements, and laboratory data were compared between the baseline and the first, third, and sixth months. Results: Body mass index (BMI) was higher among those with a low educational level. The mean age, the number of medications used, and the metabolic parameter values were significantly lower among the participants who did not have a chronic disease. Blood pressures, weight, BMI, plasma glucose and insulin, HOMA-IR, and triglyceride were statistically significantly higher at the baseline compared to follow-up values. Fasting plasma glucose was higher at the baseline in diabetic patients. The results were compared with Student t and One Way ANOVA tests. The Pearson correlation coefficient was used to demonstrate the association between baseline and repeated metabolic measurements. Conclusion: The trans-theoretical model is effective in managing adult obese and overweight individuals and also in glycemic control in obese Type-2 diabetics.

2.
J Turk Ger Gynecol Assoc ; 24(4): 235-240, 2023 12 06.
Artigo em Inglês | MEDLINE | ID: mdl-37882616

RESUMO

Objective: Osteoporosis is a substantial global public health issue. The objective of this study was to evaluate the risk variables associated with osteoporosis among patients seeking care at an outpatient menopausal clinic in a tertiary university hospital. Material and Methods: In this retrospective, cross-sectional study postmenopausal women who attended the outpatient menopause clinic of Baskent University Hospital between June 01, 2014, and August 31, 2015, were enrolled. Patients' datasheets were reviewed and data including age, body mass index, parity, duration and age of menopause, history of smoking and oral contraceptive pills (OCPs) use, natural or surgical menopause, and calcium-containing food consumption were collected through a standardized questionnaire. Bone mineral density (BMD) was measured at the femur neck and lumbar spine by dual energy X-ray absorptiometry. Results: A total of 1,148 women with a mean age of 53.5±6.7 years, mean duration of menopause 7.1±6.2 years and mean age of menopause 46.3±5.1 years were identified. Of these, 235 (20.5%) were diagnosed as having osteoporosis. The average femur and lumbar T-values showed a decrease in normal weight patients compared to overweight, obese, and morbidly obese patients (F=22,337, p<0.001 and F=50,195, p<0.001, respectively). The mean femur T-values were higher in participants who used OCPs, regularly consumed a calcium-rich diet, and performed regular physical activity (p<0.05, p<0.01 and p<0.05). Positive correlations were noted between giving birth and femur T-values (r=0.065, p=0.027), between natural menopause and lumbar T-values (r=0.060, p=0.043), and between consuming a calcium-rich diet and femur T-values (r=0.087, p=0.003 and r=0.064, p=0.031, respectively). Conclusion: Using OCPs, lifelong physical activity, and a healthy diet rich in calcium are important factors for the prevention of low lumbar spine and femoral BMD and by implication, osteoporosis.

3.
Transpl Immunol ; 81: 101916, 2023 12.
Artigo em Inglês | MEDLINE | ID: mdl-37567484

RESUMO

Transplant physicians should be aware of the immune deviation-related clinical conditions as allogeneic hematopoietic stem cell transplantation is widely used for the treatment of patients with malignant and non-malignant disorders. Neurological manifestations and graft-versus-host disease (GVHD) may commonly develop in transplant recipients. However, overlapping clinical immunological conditions may lead to diagnostic challenges. Herein, we discussed the differential diagnosis of a patient with immune reconstitution inflammatory syndrome (IRIS) developing on the basis of chronic GVHD.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Humanos , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Transplante de Células-Tronco , Doença Enxerto-Hospedeiro/terapia , Transplante Homólogo
4.
Exp Clin Transplant ; 2022 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-35297337

RESUMO

OBJECTIVES: Patients with adult sickle cell disease and severe sequelae are treated with nonmyeloablative allogeneic hematopoietic stem cell transplant. So far, data on gonadal effects are lacking for older cured patients. We assessed the gonadal reserve and sexual function of patients cured of sickle cell disease with transplant and with anti-T-lymphocyte globulin and posttransplant cyclophosphamide-containing regimen within the context of the Baskent Organ Damage Mitigation and Medical Care Development Program. MATERIALS AND METHODS: All adult patients (≥18 years) with sickle cell disease who underwent peripheral stem cell transplant from September 2013 to July 2019 and were graft-versus-host disease free for 2 years and not immunosuppressed were invited to participate in this prospective observational study. Of 61 eligible patients, 43 participants (~10% from international registries) were included (median age at transplant was 29 years; range, 18-45 years). Gonadal status, risk of gonadal damage posttransplant, conception, and sexual function posttransplant were evaluated. RESULTS: Allogeneic hematopoietic stem cell transplant was associated with increased risk of secondary amenorrhea (odds ratio of 93; 95% CI, 4.94-17.50; P = .002) and ovarian insufficiency (odds ratio of 37.8; 95% CI, 2.03 to -700.94; P = .014) but not with female sexual dysfunction. Secondary ovarian insufficiency developed in all women posttransplant. Transplant was associated with significant risk of azoospermia (odds ratio of 4.35; 95% CI, 1.02-18.45; P = .017). Moderate-to-severe erectile dysfunction developed in 2 men (10%). Among female participants, 1 had spontaneous conception that ended in miscarriage and 1 had term delivery after in vitro fertilization. Among male participants, 1 had a child by in vitro fertilization and 1 experienced spontaneous conception. CONCLUSIONS: Although spontaneous conception was shown in our patient group, gonadal damage was evident at >2 years posttransplant. This risk was associated with age in female patients. Better fertility preservation measures should be incorporated into medical care development programs.

5.
Exp Clin Transplant ; 2021 Aug 09.
Artigo em Inglês | MEDLINE | ID: mdl-34387156

RESUMO

Sickle cell disease is the most common genetic disorder in the Eastern Mediterranean region where our transplant center is located. Today, adult patients with sickle cell disease can also be successfully treated with allogeneic hematopoietic stem cell transplantation. Bone marrow necrosis is a rare and serious clinical condition. Herein, we present this complication for the first time in the literature, which developed in the course of allogeneic hematopoietic stem cell transplantation and was successfully managed with additional bone marrow support. The recognition, prevention, and management of this rare and potentially fatal complication, bone marrow necrosis, are vitally important, especially in regions with high prevalence of sickle cell disease.

6.
Exp Clin Transplant ; 2021 Mar 03.
Artigo em Inglês | MEDLINE | ID: mdl-33663361

RESUMO

OBJECTIVES: Reluctance of families of deceased donors to provide approval for donation is a factor in low rates of deceased donor organ transplants. Decisions of women may be important for family approval. We investigated the influence of knowledge and beliefs of housewives on attitudes toward organ donation. MATERIALS AND METHODS: This cross-sectional study was conducted with 212 housewives attending Directorate of Religious Affairs centers and public education centers in Adana province between May and June 2018. A structured questionnaire to assess sociode-mographic information, knowledge, and beliefs about organ donation, as well as the Attitudes Toward Organ Donation Scale, was applied through face-to-face interviews. RESULTS: Mean age of participants was 42.9 ± 13.1 years, 68 (32.1%) had no formal education, and 125 women (59.0%) identified as low income. Of the women, 40 (18.9%) were single, 147 (69.3%) were married, 25 (11.8%) were divorced∕widowed, 104 (49.1%) were attending religious affairs centers, and 108 (50.9%) were attending public education centers. Mean score for the question "What is the religious drawback of donating organs?" was significantly higher in participants attending a Quran course (2.5 ± 1.4), and mean score of Attitudes Toward Organ Donation Scale decreased significantly as mean score for this question increased; the score for "Are you aware that the organ donation-related procedures are conducted within the law?" was 2.2 ± 1.2 (P < .001). Scores increased as knowledge level increased (r = 0.360, P < .001), and scores decreased as perception of organ donation as religiously objectionable increased (r = -0.258, P < .001). CONCLUSIONS: Participants with sufficient knowledge about organ donation, without religious objection to organ donation, and with awareness of the lawful status of organ donation had positive attitudes toward organ donation. Efforts toward improvement of community knowledge could increase rates of deceased donor organ donation.

7.
Exp Clin Transplant ; 2021 Jan 11.
Artigo em Inglês | MEDLINE | ID: mdl-33455572

RESUMO

OBJECTIVES: Our aim was to compare patients with high-risk chronic lymphocytic leukemia referred to our transplant center who underwent allogeneic stem cell transplant with those who did not receive this treatment. Factors compared included demographics, clinical characteristics, and survival rates in the novel targeted therapy era. MATERIALS AND METHODS: All 33 patients with high-risk chronic lymphocytic leukemia who were referred to the hematopoietic stem cell transplant center were enrolled in this retrospective, single-center nonrandomized study. Outcomes of patients who received allogeneic stem cell transplant were compared with those of nontransplant patients. Chemoimmunotherapy and ibrutinib were given when indicated. Factors related to overall and progression-free survival were assessed. RESULTS: Thirteen patients underwent allotransplant, and transplant was not done in 20 patients for various reasons. Demographic and clinical features of the transplant and nontransplant groups were similar. The estimated cumulative overall survival was 72.6 ± 15 and 84.3 ± 13 months in the nontransplant and transplant groups, respectively. The 5-year overall and progression-free survival rates in the transplant and nontransplant groups were 57.3%/36.0% and 40%/20.6%, respectively. In the nontransplant group, overall survival of those who used ibrutinib was longer than overall survival in patients in the transplant group who used the same drug, but the difference was not statistically significant. Although not significant, overall survival in patients who did not use ibrutinib was longer in the transplant group than in the nontransplant group. Cox regression analyses showed that transplant, relapse, and Binet stage were independent predictors of overall survival. CONCLUSIONS: In patients who do not use ibrutinib, allogeneic stem cell transplant improved survival compared with nontransplant patients. Addition of ibrutinib provided comparable life expectancies, showing that allogeneic stem cell transplant and ibrutinib may have complementary roles. Transplant is still an independent predictor of overall survival.

8.
Exp Clin Transplant ; 19(8): 856-864, 2021 08.
Artigo em Inglês | MEDLINE | ID: mdl-31424361

RESUMO

OBJECTIVES: Our aim was to identify factors associated with overall survival and the efficacy of postrelapse treatment protocols and to determine whether pretransplant consolidation therapy and minimal residual disease status pose a survival benefit. MATERIALS AND METHODS: Patients with acute myeloid leukemia who underwent stem cell transplant between 2007 and 2018 were enrolled retrospectively. The effects of pretransplant cytogenetic and minimal residual disease status, pretransplant consolidation therapies, development of graft-versus-host disease, postrelapse treatment protocols, and type of con-ditioning regimens on overall survival were analyzed. RESULTS: In 76 study patients, the cumulative overall 1- and 5-year relapse probabilities were 67.8% and 58.7%, respectively. Overall survival rates at 3 and 5 years in patients with and without relapse were 23.5% and 0% and 95.9% and 91.1% (P < .001), respectively. Although mean postrelapse overall survival was better with intensive salvage plus donor lymphocyte infusion, no significant differences were shown versus other therapies (intensive salvage, nonintensive salvage, intensive salvage or nonintensive salvage plus donor lymphocyte infusion, or supportive therapy). Twenty-three patients (30.3%) died during the study period with a median survival of 9.6 months. Patients with favorable, intermediate, and unfavorable cytogenetic status showed overall survival of 46.6 ± 10.4, 54.6 ± 4.4, and 36.9 ± 5.9 months (P = .807). Patients with and without minimal residual disease and patients who received or did not receive consolidation therapy had similar overall survival. Relapse was an independent predictor of overall survival (increased mortality risk of 26.22). Patients who developed graft-versus-host disease showed decreased relapse. CONCLUSIONS: Relapse is the most important predictor of overall survival and is associated with poor prognosis. Pretransplant minimal residual status and cytogenetic status showed no effect on relapse rates and overall survival, and consolidation therapy did not improve outcomes.


Assuntos
Doença Enxerto-Hospedeiro , Transplante de Células-Tronco Hematopoéticas , Leucemia Mieloide Aguda , Doença Crônica , Doença Enxerto-Hospedeiro/diagnóstico , Doença Enxerto-Hospedeiro/etiologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Humanos , Leucemia Mieloide Aguda/diagnóstico , Leucemia Mieloide Aguda/genética , Leucemia Mieloide Aguda/terapia , Neoplasia Residual/etiologia , Recidiva , Estudos Retrospectivos , Resultado do Tratamento
9.
Clin Lab ; 66(8)2020 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-32776750

RESUMO

BACKGROUND: Anemia is a frequent disorder worldwide. Iron deficiency anemia (IDA) is the most common form of anemia. Although oral iron is the first choice for treatment, the efficacy of oral iron preparations may be limited. Ferric carboxymaltose (FCM) is a novel parenteral iron preparation which can rapidly replenish iron stores. The aim of the present study is to investigate the impact of FCM dose on hemoglobin (Hb) and ferritin levels and the frequency of hypersensitivity reactions. METHODS: This study was conducted with 765 IDA patients between September 1, 2016 and September 1, 2018. He-moglobin (Hb), serum ferritin, transferrin saturation values were examined at the time of diagnosis, Hb and ferritin values at first month. RESULTS: Post-treatment Hb and ferritin levels significantly increased. The mean Hb level alteration was 2.43 ± 1.2 g/dL, the median ferritin level alteration was 157.3 ng/mL. The mean Hb level was lower and the mean change in Hb level was higher in higher doses. Allergic reactions were more frequent in higher doses. CONCLUSIONS: Ferric carboxymaltose is a novel treatment option with a low risk of hypersensitivity reactions and well tolerated even in high doses.


Assuntos
Anemia Ferropriva , Maltose , Anemia Ferropriva/diagnóstico , Anemia Ferropriva/tratamento farmacológico , Compostos Férricos/efeitos adversos , Ferritinas , Hemoglobinas/metabolismo , Humanos , Maltose/efeitos adversos , Maltose/análogos & derivados
10.
Exp Clin Transplant ; 2020 Jun 16.
Artigo em Inglês | MEDLINE | ID: mdl-32552626

RESUMO

OBJECTIVES: The aim of the present study was to investigate suicidal ideation and dissociative experiences and to predict demographic and clinical risk factors during isolation periods in patients undergoing hematopoietic stem cell transplant. MATERIALS AND METHODS: Our study included 61 consecutive stem cell recipients (29 autologous, 32 allogeneic). Patients were evaluated with the Suicidal Ideation Scale, Dissociative Experiences Scale, Hamilton Depression Scale, Hamilton Anxiety Scale, and State Trait Anxiety Inventory. RESULTS: The transplant procedure did not influence the Dissociative Experiences or Suicidal Ideation Scales (P > .05). However, patients had higher anxiety and depression levels at time of discharge (P < .001). Suicidal ideation scores were correlated with higher Hamilton Depression Scale, State Trait Anxiety Inventory, and Dissociative Experiences Scale scores on admission (P < .05), with the latter 2 scores also higher at the time of discharge in patients who received radiotherapy prior to transplant (P < .05). CONCLUSIONS: Suicidal ideation and dissociative experiences, which may emerge because of complex and traumatic processes, should be considered by clinicians. Social and psychological support should be provided for patients undergoing hematopoietic stem cell transplant.

12.
Indian J Hematol Blood Transfus ; 34(3): 495-500, 2018 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-30127560

RESUMO

The purpose of this study is to compare the efficacy and side effects of two red blood cell exchange (RBCX) transfusion systems in sickle cell disease (SCD). The data is collected retrospectively from the January 2010 to March 2015. 447 RBCX transfusions were performed to 165 patients. Side effects, clinical and technical efficacy were compared in between procedures with Cobe Spectra (CS) and Spectra Optia (SO) systems. Furthermore a subgroup analyses was performed for 40 patients who had RBCX transfusions with both system at least two times. Vasoocclusive crises, preoperative period and foot ulcers (49.6, 13, and 15.2% respectively) were the common indications of RBCX transfusion. While the levels of post-RBCX HbS and the actual fraction of cells remaining (FCRa) were found significantly higher in the SO compared to CS system (p = 0.018 and p = 0.016 respectively), the rate of targeted hemoglobin S (HbS) levels (< 30%) were same in both. The length of procedure and replacement volume were significantly lower in SO compared to CS system (p = 0.025 and 0.044 respectively). Subgroup analyses of 40 patients did not reveal any statistically significant differences regarding post-procedure HbS levels, FCRa levels, replacement volume and procedure duration. The inter-rater correlation coefficient for FCRa was calculated to be 0.82. Serious adverse reactions were not observed from either system. Both systems are efficiently achieved the targeted post-procedure HbS level. The recently introduced SO apheresis system is as effective and safe as the CS system, which has been used for all indications of SCD for years.

14.
Exp Clin Transplant ; 16 Suppl 1(Suppl 1): 47-50, 2018 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-29527991

RESUMO

OBJECTIVES: Allogeneic hematopoietic stem cell transplant is a curative treatment option for many hematologic diseases. The existence of a fully compatible donor for recipients is the first condition for minimized transplant-related mortality and morbidity. The best donor for hematopoietic stem cell transplant is an HLA-matched sibling donor. The possibility of finding an HLA-matched sibling is less than 30% worldwide. Hematopoietic stem cell transplant is needed for an increasing number of patients every year, but the ability to find a fully compatible donor has limited its use. MATERIALS AND METHODS: From August 2012 to May 2017, we screened 412 adult patients who required AHSCT and their families for HLA tissue groups who were seen at our center (Baskent University Adana Dr. Turgut Noyan Research and Medical Center Hematology Unit). To screen tissue groups at our center, we perform lowresolution typing for HLA-A, -B, -C, -DRB1, and -DQB. If an HLA genotype cannot be identified, verification typing is done using highresolution testing. RESULTS: We found matched family donors in 227 (55%) of 412 patients screened at our center. The ratio of HLAmatched related donors was 83% for 279 patients who received allogeneic stem cell transplant. CONCLUSIONS: The likelihood of finding eligible unrelated donors has been gradually increasing, in part due to the development of the National Bone Marrow Bank. However, a careful screening for related donors is still important. Our findings indicate the importance of careful examination of family genealogy and of careful family screening in our region.


Assuntos
Família , Transplante de Células-Tronco Hematopoéticas , Doadores Vivos/provisão & distribuição , Feminino , Testes Genéticos , Genótipo , Doença Enxerto-Hospedeiro/genética , Doença Enxerto-Hospedeiro/imunologia , Doença Enxerto-Hospedeiro/prevenção & controle , Antígenos HLA/genética , Antígenos HLA/imunologia , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Histocompatibilidade , Teste de Histocompatibilidade , Humanos , Masculino , Valor Preditivo dos Testes , Fatores de Risco , Transplante Homólogo , Resultado do Tratamento , Turquia
15.
Hematol Oncol Stem Cell Ther ; 11(3): 149-157, 2018 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-29474820

RESUMO

OBJECTIVE/BACKGROUND: Anti-T lymphocyte globulin Fresenius (rATG-F; ATG-Fresenius) and antithymocyte globulin (thymoglobulin), which are included in transplant protocols, are used to reduce the risk of chronic graft-versus-host disease (cGVHD) or suppress allograft rejection. Available clinical studies have been conducted in heterogenous patient populations and with different administration protocols including stem cell sources. Additionally, the pharmacokinetics of ATG is variable, and the clinically effective dose of rATG-F, in particular, is not exactly known. The aim of the study was to investigate the clinical outcomes of acute myeloid leukemia (AML) patients who underwent hemopoietic peripheral stem cell transplantation from full-matched sibling donors and given two different doses of r-ATG-F. METHODS: This was a single-center, retrospective chart review conducted between July 2005 and July 2016. Sixty-nine consecutive AML patients who underwent transplant with fludarabine- and busulfan-based conditioning were included in the study. Patients in Group 1 received 15 mg/kg body weight rATG-F to 2013 (n = 46), and Group 2 received 30 mg/kg of rATG-F dose begining in 2013 to reduce to cGVHD (n = 23). Cyclosporine and methotrexate were used to treat acute GVHD (aGVHD) prophylaxis. Outcome parameters were compared between the groups. RESULTS: Although the recommended dose r-ATG-F had led to a decrease in the cumulative incidence of cGVHD (27 [58.7%] vs. 8 [34.8%]; p = .03), it also increased the infection rate at 1 year (3 [6.5%] vs. 4 [17.4%]; p = .02). The two groups were similar in terms of engraftment time, aGVHD, relapse, nonrelapse mortality, and rATG-F-related toxicity. A Cox regression model revealed that aGVHD III-IV was associated with increased nonrelapse mortality at 1 year (hazard ratio = 18.2; 95% confidence interval, 1.667-199.255; p = <.02). No patients developed rATG-F-related severe adverse events (Common Terminology Criteria grade 4 or 5). CONCLUSION: Dose difference of rATG-F did not influence survival parameters; however, increasing the dose to 30 mg/kg seems to be effective for reducing cGVHD with an increase in infection rate requiring close monitoring of infections in AML patients who received myeloablative fludarabine/busulfan conditioning.


Assuntos
Soro Antilinfocitário/administração & dosagem , Bussulfano/administração & dosagem , Leucemia Mieloide Aguda , Irmãos , Transplante de Células-Tronco , Doadores de Tecidos , Condicionamento Pré-Transplante , Vidarabina/análogos & derivados , Adulto , Aloenxertos , Intervalo Livre de Doença , Feminino , Doença Enxerto-Hospedeiro/prevenção & controle , Humanos , Leucemia Mieloide Aguda/mortalidade , Leucemia Mieloide Aguda/terapia , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Taxa de Sobrevida , Vidarabina/administração & dosagem
16.
Medicine (Baltimore) ; 97(6): e9844, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-29419693

RESUMO

The Eastern Mediterranean is among the regions where sickle cell disease (SCD) is common. The morbidity and mortality of this disease can be postponed to adulthood through therapies implemented in childhood. The present study focuses on the organ damage-reducing effects of the Baskent Sickle Cell Medical Care Development Program (BASCARE), which was developed by a team who lives in this region and has approximately 25 years of experience. The deliverables of the program included the development of an electronic health recording system (PRANA) and electronic vaccination system; the use of low citrate infusion in routine prophylactic automatic erythrocyte exchange (ARCE) programs including pregnant women; the use of leukocyte-filtered and irradiated blood for transfusion; the use of magnetic resonance imaging methods (T2) for the management of transfusion-related hemosiderosis; and the implementation of an allogeneic hematopoietic stem cell transplantation protocol for adult patients. The sample was composed of 376 study subjects and 249 control subjects. The hospital's Data Management System and the central population operating system were used for data collection. BASCARE enabled better analysis and interpretation of complication and mortality data. Vaccination rates against influenza and pneumococcal disease improved (21.5% vs 50.8% and 21.5% vs 49.2%, respectively). Effective and safe ARCE with low citrate infusion were maintained in 352 subjects (1003 procedures). Maternal and fetal mortality was prevented in 35 consecutive pregnant patients with ARCE. Chelating therapy rates reduced from 6.7% to 5%. Successful outcomes could be obtained in all 13 adult patients who underwent allogeneic peripheral stem cell transplantation from a fully matched, related donor. No patients died by day 100 or after the first year. Cure could be achieved without graft loss, grades III to IV acute graft versus host disease, extensive chronic graft versus host disease, or other major complications. The BASCARE program significantly improved patient care and thereby prolonged the life span of SCD patients (42 ± 13 years vs 29 ±â€Š7 years, P < .001). We may recommend using such individualized programs in centers that provide health care for patients with SCD, in accordance with holistic approach due to the benign nature but malignant course of the disease.


Assuntos
Anemia Falciforme , Avaliação de Processos e Resultados em Cuidados de Saúde/estatística & dados numéricos , Administração dos Cuidados ao Paciente , Adulto , Anemia Falciforme/epidemiologia , Anemia Falciforme/terapia , Registros Eletrônicos de Saúde/organização & administração , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Mortalidade , Administração dos Cuidados ao Paciente/métodos , Administração dos Cuidados ao Paciente/organização & administração , Administração dos Cuidados ao Paciente/estatística & dados numéricos , Gravidez , Serviços Preventivos de Saúde/métodos , Desenvolvimento de Programas , Turquia/epidemiologia
17.
J Clin Apher ; 33(1): 65-71, 2018 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-28699692

RESUMO

BACKGROUND AND OBJECTIVE: Assessment of Hemoglobin S trait donors has gained importance together with the increased allogeneic peripheral stem cell transplant activity for sickle cell disease in the regions where the disease is prevalent. Outcomes of Granulocyte-Colony Stimulating Factor (G-CSF) administration are obscure for hemoglobin S trait donors. This study aims at investigating the incidence of hemoglobin S carrier status and outcomes of G-CSF administration among donors who live in Eastern Mediterranean region. MATERIAL AND METHOD: The cross-sectional, single-center cohort study was performed with 147 donors between January 2013 and March 2017. Prevalence of hemoglobin S trait was estimated and subjects with or without Hemogobin S trait were compared with regard to stem cell characteristics, early and late clinical outcomes after G-CSF administration. RESULTS: Eleven out of 147 donors (7.48%) were found as hemoglobin S trait. G-CSF administration was successfully completed and yielded good harvesting results in hemoglobin S trait donors. No statistically significant difference was found between groups with regard to early and late side effects, stem cell characteristics. Blood pressures and QTc values were within normal ranges in both groups. Groups were similar with regard to CD34 values. CONCLUSION: G-CSF seems safe in hemoglobin S trait donors. Their being eligible as donors would increase the chance of the patients for allogeneic stem cell transplantation in high prevalence regions. Further studies are required to reveal the safety profile of G-SCF in hemoglobin S carriers in different regions.


Assuntos
Fator Estimulador de Colônias de Granulócitos/administração & dosagem , Mobilização de Células-Tronco Hematopoéticas/métodos , Traço Falciforme , Doadores de Tecidos , Adulto , Estudos de Coortes , Estudos Transversais , Feminino , Hemoglobina Falciforme , Humanos , Masculino , Região do Mediterrâneo , Pessoa de Meia-Idade
18.
Pak J Med Sci ; 33(3): 549-553, 2017.
Artigo em Inglês | MEDLINE | ID: mdl-28811769

RESUMO

OBJECTIVE: In this study, we investigated the influence of electronic health records (EHR) and electronic vaccination schedule applications on the vaccination status of patients who were admitted to our Center for the treatment of sickle cell disease (SCD). METHODS: The vaccination status against influenza and pneumococcus infection was determined in 93 patients who were admitted to the hematology outpatient clinic, Baskent University Adana Hospital from April 2004 to March 2009. The vaccination status was then re-evaluated following establishment of EHR and electronic vaccination schedules in 2012. RESULTS: Of the 93 patients with SCD 21.5% (n = 20) were vaccinated against pneumococcus and 21.5% (n = 20) were regularly vaccinated against influenza. When the vaccination rates of 59 of 93 patients who presented for their regular control examinations were analyzed following establishment of EHR and vaccination schedules in 2012, these rates were 49.2% (n = 29) and 50.8% (n = 30) for influenza and pneumococcus, respectively, after EHR; there were 23.7% (n = 14) and 20.3% (n = 12), respectively, before EHR. A statistically significant difference was found between the vaccination rates before and after EHR (p < 0.05). CONCLUSION: Although viral and bacterial infections are life-threatening health problems in patients with SCD, the vaccination rates were low in high-risk patients. However, these rates increased after application of electronic vaccination schedules.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...